



MGFA Study Web Content:

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

Recruitment Information:

Study Type: Interventional (Clinical Trial)

Status: Recruiting

Target Patient: Participants with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing standard of care therapy.

Eligible Ages: ≥18 years

Link to appropriate websites

<https://clinicaltrials.gov/ct2/show/NCT03772587?term=Momenta&rank=10>

Inclusion and Exclusion Criteria:

Inclusion/Exclusion Criteria: Participants must be ≥18 years of age with a documented history of Generalized Myasthenia Gravis (gMG) and clinical signs/symptoms of gMG, not pregnant or breastfeeding, and no history of any neurologic disorder other than MG that might interfere with the accuracy of study assessments. Additional, more specific criteria are defined in the protocol.

Study Information:

Sponsor: Momenta Pharmaceuticals, Inc.

Type of Study: Phase 2 Parallel Assignment Quadruple Blind

Single Center/Multi-center: Multi-center

Travel Funds Available: Y N

Find A Center Near You:

For a current list of open clinical trial sites, please visit clinicaltrials.gov and search “M281 myasthenia gravis”. You may also contact Momenta at clinicaltrialinfo@momentapharma.com